Unveiling the full potential of flexible receptor docking using multiple crystallographic structures

Journal of Medicinal Chemistry

Volumn 48, Issue 13, 2005, Pages 4432-4443

  Barril, Xavier ^a   Morley, S David ^a,b  

^a Vernalis PLC   (United Kingdom)

^b Old Police Station   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; DOCKING PROTEIN; HEAT SHOCK PROTEIN 90; RECEPTOR PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; PREDICTION; PROTEIN BINDING; VIRTUAL REALITY; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CDC2-CDC28 KINASES; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DATABASES, PROTEIN; HSP90 HEAT-SHOCK PROTEINS; KINETICS; MODELS, MOLECULAR; RECEPTORS, CELL SURFACE; RECEPTORS, DRUG; THERMODYNAMICS;

EID: 21244479779     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm048972v     Document Type: Article

References (65)

1. Brooijmans, N.; Kuntz, I. D. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 335-373.
2. Nicklaus, M. C.; Wang, S.; Driscoll, J. S.; Milne, G. W. Conformational changes of small molecules binding to proteins. Bioorg. Mad. Chem. 1995, 3, 411-428.
3. Perola, E.; Charifson, P. S. Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. J. Med. Chem. 2004, 47, 2499-2510.
4. Teague, S. J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discovery 2003, 2, 527-541.
5. Erickson, J. A.; Jalaie, M.; Robertson, D. H.; Lewis, R. A.; Vieth, M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J. Med. Chem. 2004, 47, 45-55.
6. Good, A. C.; Cheney, D. L. Analysis and optimization of structure-based virtual screening protocols (1): exploration of ligand conformational sampling techniques. J. Mol. Graph. Modell. 2003, 22, 23-30.
7. Cecchini, M.; Kolb, P.; Majeux, N.; Caflisch, A. Automated docking of highly flexible ligands by genetic algorithms: a critical assessment. J. Comput. Chem. 2004, 25, 412-422.
8. Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design. Mol. Pharmacol. 2000, 57, 213-218.
9. Leach, A. R. Ligand docking to proteins with discrete side-chain flexibility. J. Mol. Biol. 1994, 235, 345-356.
10. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997, 215-220.
11. Taylor, R. D.; Jewsbury, P. J.; Essex, J. W. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function. J. Comput. Chem. 2003, 24, 1637-1656.
12. Knegtel, R. M.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of protein structures. J. Mol. Biol. 1997, 266, 424-440.
13. Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T. FlexE: efficient molecular docking considering protein structure variations. J. Mol. Biol. 2001, 308, 377-395.
14. Osterberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002, 46, 34-40.
15. Lin, J. H.; Perryman, A. L.; Schames, J. R.; McCammon, J. A. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme. Biopolymers 2003, 68, 47-62.
16. Stewart, L.; Clark, R.; Behnke, C. High-throughput crystallization and structure determination in drug discovery. Drug Discovery Today 2002, 7, 187-196.
17. Fradera, X.; de la Cruz, X.; Silva, C. H.; Gelpi, J. L.; Luque, F. J.; Orozco, M. Ligand-induced changes in the binding sites of proteins. Bioinformatics 2002, 18, 939-948.
18. Murray, C. W.; Baxter, C. A.; Frenkel, A. D. The sensitivity of the results of molecular docking to induced fit effects: application to thrombin, thermolysin and neuraminidase. J. Comput.-Aided Mol. Des 1999, 13, 547-562.
19. McGovern, S. L.; Shoichet, B. K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem. 2003, 46, 2895-2907.
20. Frimurer, T. M.; Peters, G. H.; Iversen, L. F.; Andersen, H. S.; Moller, N. P.; Olsen, O. H. Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities. Biophys. J. 2003, 84, 2273-2281.
21. Cavasotto, C. N.; Abagyan, R. A. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 2004, 337, 209-225.
22. Wei, B. Q.; Weaver, L. H.; Ferrari, A. M.; Matthews, B. W.; Shoichet, B. K. Testing a flexible-receptor docking algorithm in a model binding site. J. Mol. Biol. 2004, 337, 1161-1182.
23. Ferrari, A. M.; Wei, B. Q.; Constantino, L.; Shoichet, B. K. Soft Docking and Multiple Receptor Conformations in Virtual Screening. J. Med. Chem. 2004, in press.
24. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000, 60, 3689-3695.
25. McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P. M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; Zhelev, N.; Zheleva, D.; Lane, D. P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102, 463-468.
26. Maloney, A.; Workman, P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24.
27. Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 2003, 3, 377-383.
28. Dutta, R.; Inouye, M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 2000, 25, 24-28.
29. Bergerat, A.; de Massy, B.; Gadelle, D.; Varoutas, P.C.; Nicolas, A.; Forterre, P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 1997, 386, 414-417.
30. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonds in biological molecules. Proc. Natl. Acad. Sci. U. S. A 2004.
31. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, 11, 775-785.
32. Gohlke, H.; Hendlich, M.; Klebe, G. Predicting binding modes, binding affinities and 'hot spots' for protein-ligand complexes using a knowledge-based scoring function. Perspect. Drug Discovery Des. 2000, 20, 115-144.
33. Fradera, X.; Mestres, J. Guided docking approaches to structure-based design and screening. Curr. Top. Med. Chem. 2004, 4, 687-700.
34. Fradera, X.; Knegtel, R. M.; Mestres, J. Similarity-driven flexible ligand docking. Proteins 2000, 40, 623-636.
35. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des 2002, 16, 129-149.
36. Joseph-McCarthy, D.; Thomas, B. E.; Belmarsh, M.; Moustakas, D.; Alvarez, J. C. Pharmacophore-based molecular docking to account for ligand flexibility. Proteins 2003, 51, 172-188.
37. Barril, X.; Hubbard, R. E.; Morley, S. D. Virtual Screening in Structure-Based Drug Design. Mini-Rev. Med. Chem. 2004, 4, 779-791.
38. Shoichet, B. K. Virtual screening of chemical libraries. Nature 2004, 432, 862-865.
39. Davis, A. M.; Teague, S. J.; Kleywegt, G. J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem., Int. Ed Engl. 2003, 42, 2718-2736.
40. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
41. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
42. InsightII, Release 2000; Accelrys Inc.: San Diego, CA, 2002.
43. Word, J. M.; Lovell, S. C.; Richardson, J. S.; Richardson, D. C. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 1999, 285, 1735-1747.
44. Zhang, L.; Hermans, J. Hydrophilicity of cavities in proteins. Proteins 1996, 24, 433-438.
45. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital-electronegativity - A rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
46. Molecular Operating Environment (MOE), version 2003.02; Chemical Computing Group Inc.: Montreal, Canada, 2003.
47. Birch, L.; Murray, C. W.; Hartshorn, M. J.; Tickle, I. J.; Verdonk, M. L. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. J. Comput.-Aided Mol. Des 2002, 16, 855-869.
48. Bradley, E. K.; Miller, J. L.; Saiah, E.; Grootenhuis, P. D. Informative library design as an efficient strategy to identify and optimize leads: application to cyclin-dependent kinase 2 antagonists. J. Med. Chem. 2003, 46, 4360-4364.
49. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic Generation of 3D-Atomic Coordinates for Organic Molecules. Tetrahedron Comput. Methodol. 1990, 3, 537-547.
50. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
51. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 2002, 42, 1273-1280.
52. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
53. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discovery 2004, 3, 660-672.
54. Knowles, D. Towards a fully integrated strategy for structure-based drug discovery. Curr. Drug Discovery 2002, 31-35.
55. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davies, B.; Drysdale, M.; Dymock, B.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R. E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J. Chem. Inf. Model. 2004, in press.
56. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
57. Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
58. Drysdale, M. J.; Dymock, B. W.; Barril-Alonso, X.; Workman, P.; Pearl, L. H.; Promodrou, C.; MacDonald, E. Preparation of 3,4-diarylpyrazoles as inhibitors of heat shock protein 90 (HSP90) and their use in the therapy of cancer. WO 03/055860, 2003.
59. Kreusch, A.; Han, S.; Brinker, A.; Zhou, V.; Choi, H. S.; He, Y.; Lesley, S. A.; Caldwell, J.; Gu, X. J. Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 1475-1478.
60. Barril-Alonso, X.; Dymock, B. W.; Drysdale, M. J.; Fromont, C.; Jordan, A. Pyrimidothiophene compounds. WO 2005/021552, 2005.
61. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R. E. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J. Chem. Inf. Comput. Sci. 2004, 44, 643-651.
62. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., III Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33, 889-897.
63. Aqvist, J.; Luzhkov, V. B.; Brandsdal, B. O. Ligand binding affinities from MD simulations. Acc. Chem. Res. 2002, 35, 358-365.
64. Morley, S. D.; Afshar, M. Validation of an empirical RNA-ligand scoring function for fast flexible docking using RiboDock. J. Comput.-Aided Mol. Des 2004, 18, 189-208.
65. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.